Background: Tuberculosis (TB) is a deadly infectious disease caused by the pathogen
Mycobacterium tuberculosis (Mtb). Approximately, 1.8 and 1.3 million people are infected and
die, from TB each year as estimated by the World Health Organization. Due to increase in the incidence
of drug-resistant strains of Mtb, there is an urgent need to accelerate research which focuses
on the development of new drugs with novel mechanism of action that can treat both drugsensitive
and resistant TB infections.
Objective: The purpose of this review study was to describe vitamins as drug target that can be explored
to develop new anti tubercular drugs that can treat both drug-sensitive and resistant TB infections.
Method: The methodological approaches include literature review which is performed in the databases
like PubMed, Web of Science, Scopus, Springer and Science Direct, etc. On the basis of
evaluation of literature sources, the review was complied.
Results: This review study demonstrated that vitamins biosynthesis pathway could be used in the
development of novel drug targets. Further sequencing of the Mtb genome facilitated research in
target identification and validation that make possible the discovery of novel anti-TB agent with
new mechanisms of action. Several compounds were identified, which target vitamin biosynthesis
pathway /enzymes. Some other new targets were also identified and can be explored for the identification
of novel structural moiety.
Conclusion: Further exploration of these compounds which have been identified to target these
vitamins related novel target pathways /molecules could led to the development of antitubercular
drug which can be used in the treatment of drug sensitive and resistant TB.